Nabriva Therapeutics AG - Company Profile (NASDAQ:NBRV)

About Nabriva Therapeutics AG - (NASDAQ:NBRV)

Nabriva Therapeutics AG - logoNabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP). The Company also develops BC-7013, a semi-synthetic compound derived from pleuromutilin for the topical treatment of Gram-positive infections, including uncomplicated skin and skin structure infections (uSSIs). It is a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna, Austria.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NBRV
  • CUSIP: N/A
  • Web: www.nabriva.com
Capitalization:
  • Market Cap: $272.23 million
  • Outstanding Shares: 27,196,000
Average Prices:
  • 50 Day Moving Avg: $10.47
  • 200 Day Moving Avg: $8.60
  • 52 Week Range: $3.52 - $12.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.64
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $6.48 million
  • Price / Sales: 42.01
  • Book Value: $2.84 per share
  • Price / Book: 3.52
Profitability:
  • EBIDTA: ($54,810,000.00)
Debt:
  • Current Ratio: 5.87%
  • Quick Ratio: 5.87%
Misc:
  • Average Volume: 24,316 shs.
  • Beta: 1.23
  • Short Ratio: 3.58
 

Frequently Asked Questions for Nabriva Therapeutics AG - (NASDAQ:NBRV)

What is Nabriva Therapeutics AG -'s stock symbol?

Nabriva Therapeutics AG - trades on the NASDAQ under the ticker symbol "NBRV."

How were Nabriva Therapeutics AG -'s earnings last quarter?

Nabriva Therapeutics AG - (NASDAQ:NBRV) posted its quarterly earnings results on Wednesday, November, 16th. The company reported ($0.66) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.11. View Nabriva Therapeutics AG -'s Earnings History.

Where is Nabriva Therapeutics AG -'s stock going? Where will Nabriva Therapeutics AG -'s stock price be in 2017?

6 analysts have issued twelve-month target prices for Nabriva Therapeutics AG -'s shares. Their predictions range from $13.00 to $22.00. On average, they anticipate Nabriva Therapeutics AG -'s share price to reach $16.00 in the next year. View Analyst Ratings for Nabriva Therapeutics AG -.

What are analysts saying about Nabriva Therapeutics AG - stock?

Here are some recent quotes from research analysts about Nabriva Therapeutics AG - stock:

  • 1. According to Zacks Investment Research, "Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. " (5/27/2017)
  • 2. Needham & Company LLC analysts commented, "Nabriva reported 4Q16 financial results last week. Top- line results from LEAP1, first of two ongoing Phase 3 trials of lefamulin in Community Pneumonia (CABP), are expected 3Q17. This trial is evaluating both IV and oral formulations. Top-line results from LEAP2, which is evaluating only oral formulation, are expected 1Q18 (was 4Q17). We are favorably inclined based on Phase 2 IV skin infection trial, Phase 1 oral PK trial, and Phase 1 lung trial. We believe Solithera (Cempra) is unlikely to reach market, creating a vacuum in outpatient CABP space. If lefamulin is found to have particularly safe profile, drug may ultimately be useful not only in hospital setting for severe CABP , but also in much broader outpatient setting." (3/27/2017)
  • 3. Wedbush analysts commented, "Nabriva recently reported that LEAP-1 has achieved 60% of its enrollment target, remaining on track to report data from both Ph 3 studies in 2H17 ' we believe both these readouts will be positive. In addition, we believe lefamulin's product profile possesses the key attributes required to take advantage of the commercial opportunity in CABP." (1/31/2017)

Who are some of Nabriva Therapeutics AG -'s key competitors?

Who owns Nabriva Therapeutics AG - stock?

Nabriva Therapeutics AG -'s stock is owned by a number of of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (7.92%), Omega Fund Management LLC (4.21%), EcoR1 Capital LLC (0.97%), Tekla Capital Management LLC (0.86%), Boxer Capital LLC (0.65%) and Nationwide Fund Advisors (0.64%). Company insiders that own Nabriva Therapeutics AG - stock include George Harrison Talbot and Hbm Healthcare Investments (Ca. View Institutional Ownership Trends for Nabriva Therapeutics AG -.

Who sold Nabriva Therapeutics AG - stock? Who is selling Nabriva Therapeutics AG - stock?

Nabriva Therapeutics AG -'s stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC and United Services Automobile Association. Company insiders that have sold Nabriva Therapeutics AG - stock in the last year include George Harrison Talbot and Hbm Healthcare Investments (Ca. View Insider Buying and Selling for Nabriva Therapeutics AG -.

Who bought Nabriva Therapeutics AG - stock? Who is buying Nabriva Therapeutics AG - stock?

Nabriva Therapeutics AG -'s stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Nationwide Fund Advisors, Almanack Investment Partners LLC. and Geode Capital Management LLC. View Insider Buying and Selling for Nabriva Therapeutics AG -.

How do I buy Nabriva Therapeutics AG - stock?

Shares of Nabriva Therapeutics AG - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nabriva Therapeutics AG - stock cost?

One share of Nabriva Therapeutics AG - stock can currently be purchased for approximately $10.01.

Analyst Ratings

Consensus Ratings for Nabriva Therapeutics AG - (NASDAQ:NBRV) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00 (59.84% upside)

Analysts' Ratings History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017WedbushReiterated RatingOutperform$13.00HighView Rating Details
5/12/2017HC WainwrightReiterated RatingBuyLowView Rating Details
5/11/2017Cantor FitzgeraldSet Price TargetBuy$16.00LowView Rating Details
3/27/2017Needham & Company LLCReiterated RatingBuy$15.00LowView Rating Details
12/20/2016Royal Bank of CanadaSet Price TargetBuy$22.00N/AView Rating Details
10/27/2016Leerink SwannReiterated RatingOutperform$14.00N/AView Rating Details
1/27/2016GabelliInitiated CoverageBuy$14.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Earnings by Quarter for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Earnings History by Quarter for Nabriva Therapeutics AG - (NASDAQ:NBRV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/16/2016Q3($0.55)($0.66)$1.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nabriva Therapeutics AG - (NASDAQ:NBRV)
2017 EPS Consensus Estimate: ($2.21)
2018 EPS Consensus Estimate: ($1.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.60)($0.55)($0.58)
Q2 20172($0.60)($0.56)($0.58)
Q3 20172($0.62)($0.56)($0.59)
Q4 20172($0.50)($0.43)($0.47)
Q1 20181($0.43)($0.43)($0.43)
Q2 20181($0.44)($0.44)($0.44)
Q3 20181($0.46)($0.46)($0.46)
Q4 20181($0.47)($0.47)($0.47)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Institutional Ownership Percentage: 42.86%
Insider Trades by Quarter for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Institutional Ownership by Quarter for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Insider Trades by Quarter for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017George Harrison TalbotDirectorSell325$100.56$32,682.00View SEC Filing  
5/16/2017George Harrison TalbotDirectorSell200$102.44$20,488.00View SEC Filing  
5/15/2017George Harrison TalbotDirectorSell50$101.50$5,075.00View SEC Filing  
4/28/2017Hbm Healthcare Investments (CaMajor ShareholderSell15,939$11.02$175,647.78View SEC Filing  
4/21/2017Hbm Healthcare Investments (CaMajor ShareholderSell2,622$11.04$28,946.88View SEC Filing  
4/20/2017Hbm Healthcare Investments (CaMajor ShareholderSell23,932$11.11$265,884.52View SEC Filing  
4/13/2017Hbm Healthcare Investments (CaMajor ShareholderSell32,831$11.24$369,020.44View SEC Filing  
4/10/2017Hbm Healthcare Investments (CaMajor ShareholderSell90,594$10.96$992,910.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Latest Headlines for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Source:
DateHeadline
americanbankingnews.com logoZacks Investment Research Upgrades Nabriva Therapeutics AG - (NBRV) to "Buy"
www.americanbankingnews.com - May 27 at 7:46 AM
americanbankingnews.com logoGeorge Harrison Talbot Sells 325 Shares of Nabriva Therapeutics AG - (NBRV) Stock
www.americanbankingnews.com - May 25 at 10:20 PM
finance.yahoo.com logoNabriva Commences Previously Announced Tender Offer Related to the Proposed Redomicile of its Holding Company from Austria to Ireland
finance.yahoo.com - May 23 at 10:17 AM
americanbankingnews.com logoInsider Selling: Nabriva Therapeutics AG - (NBRV) Director Sells 200 Shares of Stock
www.americanbankingnews.com - May 17 at 8:34 PM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Nabriva Therapeutics AG - Issued By Wedbush (NBRV)
www.americanbankingnews.com - May 17 at 7:46 AM
americanbankingnews.com logoNabriva Therapeutics AG - Forecasted to Earn Q1 2018 Earnings of ($0.43) Per Share (NBRV)
www.americanbankingnews.com - May 16 at 10:48 AM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 16 at 8:06 AM
americanbankingnews.com logoNabriva Therapeutics AG -'s (NBRV) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - May 15 at 4:28 PM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Nabriva Therapeutics AG - (NBRV) Issued By Leerink Swann
www.americanbankingnews.com - May 15 at 7:40 AM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Given a $16.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 13 at 5:50 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 12 at 4:40 PM
finance.yahoo.com logoNabriva Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 6:57 PM
americanbankingnews.com logo$1.54 Million in Sales Expected for Nabriva Therapeutics AG - (NBRV) This Quarter
www.americanbankingnews.com - May 3 at 4:40 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Earning Somewhat Critical Press Coverage, Report Finds
www.americanbankingnews.com - May 2 at 10:54 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Expected to Post Earnings of -$0.58 Per Share
www.americanbankingnews.com - May 1 at 11:05 AM
americanbankingnews.com logoHbm Healthcare Investments (Ca Sells 15,939 Shares of Nabriva Therapeutics AG - (NBRV) Stock
www.americanbankingnews.com - April 29 at 1:23 AM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Earns News Impact Rating of 0.07
www.americanbankingnews.com - April 27 at 11:26 PM
americanbankingnews.com logoHbm Healthcare Investments (Ca Sells 2,622 Shares of Nabriva Therapeutics AG - (NBRV) Stock
www.americanbankingnews.com - April 25 at 10:44 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Getting Somewhat Favorable Press Coverage, Analysis Shows
www.americanbankingnews.com - April 24 at 8:49 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 21 at 9:49 AM
americanbankingnews.com logoInsider Selling: Nabriva Therapeutics AG - (NBRV) Major Shareholder Sells 23,932 Shares of Stock
www.americanbankingnews.com - April 20 at 11:09 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Given News Impact Rating of -0.03
www.americanbankingnews.com - April 17 at 3:58 PM
finance.yahoo.com logoNabriva Announces the Proposed Redomicile of its Holding Company from Austria to Ireland, by means of an Exchange Offer
finance.yahoo.com - April 17 at 10:01 AM
americanbankingnews.com logoCantor Fitzgerald Reiterates "Buy" Rating for Nabriva Therapeutics AG - (NBRV)
www.americanbankingnews.com - April 14 at 5:27 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Major Shareholder Sells $369,020.44 in Stock
www.americanbankingnews.com - April 14 at 4:57 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Receives Daily Coverage Optimism Rating of 0.59
www.americanbankingnews.com - April 14 at 8:20 AM
finance.yahoo.com logoNabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin
finance.yahoo.com - April 13 at 6:30 PM
finance.yahoo.com logoNabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia
finance.yahoo.com - April 11 at 11:02 AM
finance.yahoo.com logoNabriva Therapeutics AG :NBRV-US: Earnings Analysis: 2016 By the Numbers : April 11, 2017
finance.yahoo.com - April 11 at 11:02 AM
americanbankingnews.com logoShort Interest in Nabriva Therapeutics AG - (NBRV) Drops By 0.4%
www.americanbankingnews.com - April 11 at 7:14 AM
americanbankingnews.com logoGabelli Analysts Raise Earnings Estimates for Nabriva Therapeutics AG - (NBRV)
www.americanbankingnews.com - March 30 at 10:55 AM
americanbankingnews.com logoLeerink Swann Analysts Reduce Earnings Estimates for Nabriva Therapeutics AG - (NBRV)
www.americanbankingnews.com - March 29 at 10:29 AM
americanbankingnews.com logoAnalysts Offer Predictions for Nabriva Therapeutics AG -'s Q1 2017 Earnings (NBRV)
www.americanbankingnews.com - March 29 at 10:29 AM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 27 at 1:32 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Earns Buy Rating from Needham & Company LLC
www.americanbankingnews.com - March 27 at 12:23 PM
finance.yahoo.com logoNabriva Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference
finance.yahoo.com - March 27 at 10:12 AM
finance.yahoo.com logoNabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results
finance.yahoo.com - March 24 at 6:43 PM
biz.yahoo.com logoNABRIVA THERAPEUTICS AG Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
biz.yahoo.com - March 24 at 6:43 PM
us.rd.yahoo.com logoA growing threat could kill 10 million people a year by 2050
us.rd.yahoo.com - February 24 at 4:09 PM
finance.yahoo.com logoThere's a growing threat that could kill 10 million people a year by 2050
finance.yahoo.com - February 23 at 6:49 PM
finance.yahoo.com logoAlly Bridge Group Expands European Life Science Portfolio with New Investments and Establishes Presence in Europe
finance.yahoo.com - February 21 at 6:08 PM
biz.yahoo.com logoNABRIVA THERAPEUTICS AG Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 16 at 6:20 PM
biz.yahoo.com logoNABRIVA THERAPEUTICS AG Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 13 at 7:56 PM
finance.yahoo.com logoNabriva Therapeutics to Participate in Two Investor Conferences in February
finance.yahoo.com - February 8 at 7:40 PM
streetinsider.com logoNabriva (NBRV) Says No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin
www.streetinsider.com - February 2 at 7:39 PM
biz.yahoo.com logoNABRIVA THERAPEUTICS AG Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Fina
biz.yahoo.com - January 9 at 7:28 PM
publicnow.com logoNabriva Announces Closing of Rights Offering and Underwritten Offering
us.rd.yahoo.com - December 20 at 12:43 PM
finance.yahoo.com logoNabriva Announces Results of Rights Offering and Pricing of Underwritten Offering
finance.yahoo.com - December 14 at 7:26 PM
us.rd.yahoo.com logo4:02 pm Nabriva Therapeutics announces terms of its rights offering for up to 588,127 common shares to its existing common shareholders and ADS holders
us.rd.yahoo.com - November 30 at 11:56 PM
globenewswire.com logoNabriva Announces Terms of Rights Offering
globenewswire.com - November 30 at 11:32 AM

Social

Chart

Nabriva Therapeutics AG - (NBRV) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff